Previous 10 | Next 10 |
1Q22 Galafold ® Revenue Growth of 18.5% to $78.7M New Composition of Matter Patent for Galafold ® Strengthens U.S. Patent Protection into 2038 Advancing U.S. and EU Regulatory Reviews and Launch Preparatio...
PHILADELPHIA, May 04, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Bank of America 2022 Healthcare Conference in Las Vegas, NV on Wednesday, May 11, 2022 at 12:00 p.m. P.T. A live audio webcast o...
Despite the bear market, Amicus Therapeutics is enjoying aggressive sales growth for its lead medicine, Galafold, for Fabry. By mid-year, you are most likely to see another approval, that is, AT-GAA for Pompe disease. As it's operating at a growth inflection point, you should pick...
PHILADELPHIA, April 26, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, May 9, 2022 at 8:30 a.m. ET to discuss financial results for the first quarter ended March 31, 2022. Inter...
Amicus Therapeutics (NASDAQ:FOLD) said the U.S. Patent and Trademark Office (USPTO) issued a patent which is directed to a composition of matter covering migalastat, sold as Galafold to treat Fabry disease. The company said the U.S. patent No. 11,304,940, titled 'Methods o...
PHILADELPHIA, April 19, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, announced today that the United States Patent and Trademark Office (USPT...
Although AT-GAA failed a phase 3 trial, there are reasons it could be approved. Galafold continues to do very well. I will hold until the July 29 PDUFA. For further details see: Amicus: July 29 PDUFA Makes It A Hold
Shares of Amicus Therapeutics Inc. (NASDAQ:FOLD) traded today at $25.34, eclipsing its 52-week high. Approximately 247.8 million shares have changed hands today, as compared to an average 30-day volume of 3.6 million shares. Amicus Therapeutics Inc is a biotechnology company focused on d...
Amicus Therapeutics (NASDAQ:FOLD) reported additional results from a global phase 1/2 study (ATB200-02) of AT-GAA in adult patients with Pompe disease. Pompe disease is an inherited lysosomal storage disorder caused by an enzyme deficiency that leads to accumulation of glycogen (disease ...
Meaningful and Durable Responses in Key Endpoints of Six-Minute Walk and Forced Vital Capacity for ERT-Naïve and ERT-Experienced Patients Out to 3 Years Consistent Reduction in Biomarkers Continue to Suggest a Positive Effect on Muscle Tissue S...
News, Short Squeeze, Breakout and More Instantly...
Amicus Therapeutics Inc. Company Name:
FOLD Stock Symbol:
NASDAQ Market:
Amicus Therapeutics Inc. Website:
PRINCETON, N.J., July 30, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, August 8, 2024, at 8:30 a.m. ET to discuss financial results for the second quarter ended June 30, 2024. Par...
2024-07-01 16:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
PRINCETON, N.J., June 05, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Goldman Sachs 45 th Annual Global Healthcare Conference in Miami, FL on Tuesday, June 11, 2024, at 4:00 p.m. E.T. A live audio...